Yuwei Da
YOU?
Author Swipe
View article: Effects of Thymectomy in Late‐Onset Myasthenia Gravis: A Multi‐Center Longitudinal Retrospective Study
Effects of Thymectomy in Late‐Onset Myasthenia Gravis: A Multi‐Center Longitudinal Retrospective Study Open
Objective Limited evidence has led to ongoing debate about the benefits of thymectomy for late‐onset myasthenia gravis (LOMG). This study aims to compare the outcomes of patients with LOMG who underwent thymectomy versus those who received…
View article: Dynamic Changes in Peripheral Immune Cells During Efgartigimod Treatment in Naive Generalized Myasthenia Gravis
Dynamic Changes in Peripheral Immune Cells During Efgartigimod Treatment in Naive Generalized Myasthenia Gravis Open
Background Efgartigimod is a neonatal Fc receptor (FcRn) antagonist that reduces pathogenic IgG and improves clinical symptoms in generalized myasthenia gravis (gMG). However, its immunomodulatory effects on innate and adaptive immune cell…
View article: Efficacy of Tacrolimus Plus Prednisone as Long-Term Immunosuppressive Therapy for Chronic Inflammatory Demyelinating Polyneuropathy: A Retrospective Cohort Study
Efficacy of Tacrolimus Plus Prednisone as Long-Term Immunosuppressive Therapy for Chronic Inflammatory Demyelinating Polyneuropathy: A Retrospective Cohort Study Open
Tacrolimus plus prednisone therapy demonstrated superior clinical outcomes compared to prednisone monotherapy in CIDP maintenance treatment, including accelerated symptomatic improvement, reduced relapse risk, and facilitated corticosteroi…
View article: Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study
Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study Open
Efgartigimod demonstrated robust efficacy in gMG patients. Early response was linked to shorter disease duration and severe bulbar symptoms, which promotes the identification of patients who are likely to benefit quickly from efgartigimod.
View article: Isolation of Antagonistic Bacterial Strains and Their Antimicrobial Volatile Organic Compounds Against <i>Pseudogymnoascus destructans</i> in <i>Rhinolophus ferrumequinum</i> Wing Membranes
Isolation of Antagonistic Bacterial Strains and Their Antimicrobial Volatile Organic Compounds Against <i>Pseudogymnoascus destructans</i> in <i>Rhinolophus ferrumequinum</i> Wing Membranes Open
White‐nose syndrome (WNS), caused by the fungus Pseudogymnoascus destructans ( Pd ), has led to significant mortality and species endangerment in North America. Bats in eastern China, however, carry low loads of Pd and do not exhibit disea…
View article: Short-term and long-term prognoses in AChR-Ab positive very-late-onset myasthenia gravis patients
Short-term and long-term prognoses in AChR-Ab positive very-late-onset myasthenia gravis patients Open
Background: Very-late-onset myasthenia gravis (VLOMG) refers to myasthenia gravis (MG) with onset at age 65 or older. Current research on VLOMG prognosis remains limited, especially regarding factors influencing outcomes. Objectives: To id…
View article: The Impact of COVID-19 Vaccination and Infection on the Exacerbation of Myasthenia Gravis
The Impact of COVID-19 Vaccination and Infection on the Exacerbation of Myasthenia Gravis Open
Objectives: Myasthenia Gravis (MG) is an autoimmune disorder that can exacerbate for various reasons, including vaccination and infection. This study aimed to investigate the safety of COVID-19 vaccines for MG patients, factors influencing…
View article: Integrative multi-omics analysis identifies genetically supported druggable targets and immune cell specificity for myasthenia gravis
Integrative multi-omics analysis identifies genetically supported druggable targets and immune cell specificity for myasthenia gravis Open
Background Myasthenia gravis (MG) is a chronic autoimmune disorder characterized by fluctuating muscle weakness. Despite the availability of established therapies, the management of MG symptoms remains suboptimal, partially attributed to l…
View article: P150 Ulcerative Colitis Patients’ Luminal Zinc Induces Clostridioides difficile Virulence and Exacerbates Inflammatory Responses
P150 Ulcerative Colitis Patients’ Luminal Zinc Induces Clostridioides difficile Virulence and Exacerbates Inflammatory Responses Open
Background The refractory acute severe UC patients are often complicated by C. difficile infection (CDI), resulting in higher surgery and mortality rates. However, few studies have observed C. difficile’s pathogenicity in real UC patients’…
View article: A Case Study and Literature Review of the Diagnosis of Danon Disease in Patients Presenting Only with Severe Cardiac Symptoms
A Case Study and Literature Review of the Diagnosis of Danon Disease in Patients Presenting Only with Severe Cardiac Symptoms Open
The clinical manifestations of Danon disease, which result from the primary deficiency of the lysosome-associated membrane protein 2 gene, include cardiomyopathy, skeletal myopathy, and different degrees of intellectual disability that var…
View article: Mortality of myasthenia gravis: a national population‐based study in China
Mortality of myasthenia gravis: a national population‐based study in China Open
Objective As a potentially life‐threatening condition, myasthenia gravis (MG) has limited epidemiological studies on mortality. We aim to provide demographic distribution, geographical variation, and temporal trend of MG‐related mortality …
View article: Comparison between mono‐tacrolimus and mono‐glucocorticoid in the treatment of myasthenia gravis
Comparison between mono‐tacrolimus and mono‐glucocorticoid in the treatment of myasthenia gravis Open
Objective Use of tacrolimus in mild to moderate myasthenia gravis (MG) is generally limited to glucocorticoid‐refractory cases; the advantage of mono‐tacrolimus over mono‐glucocorticoids is unknown. Methods We included mild to moderate MG …
View article: Short-term outcome prediction for myasthenia gravis: an explainable machine learning model
Short-term outcome prediction for myasthenia gravis: an explainable machine learning model Open
Background: Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness and fatigability. The fluctuating nature of the disease course impedes the clinical management. Objective: The purpose of the study was to establi…
View article: A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis
A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis Open
Background and Purpose Two clinical trials assessing the steroid-sparing effect of methotrexate (MTX) yielded conflicting results. Our objective was to investigate whether MTX would show a steroid-sparing effect in the treatment of general…
View article: Beyond the Motor Cortex: Thalamic Iron Deposition Accounts for Disease Severity in Amyotrophic Lateral Sclerosis
Beyond the Motor Cortex: Thalamic Iron Deposition Accounts for Disease Severity in Amyotrophic Lateral Sclerosis Open
Objective Previous studies have reliably identified iron deposition in the motor cortex as potential pathogenesis of amyotrophic lateral sclerosis (ALS). Here, we intended to investigate iron deposition, gray matter (GM) atrophy, and their…
View article: Tacrolimus treatment for relapsing-remitting chronic inflammatory demyelinating polyradiculoneuropathy: Two case reports
Tacrolimus treatment for relapsing-remitting chronic inflammatory demyelinating polyradiculoneuropathy: Two case reports Open
Neither patient exhibited any adverse effects due to the tacrolimus therapy. Therefore, tacrolimus can be effective for the treatment of patients with steroid-resistant CIDP.
View article: Clinical Predictors of Relapse in a Cohort of Steroid-Treated Patients With Well-Controlled Myasthenia Gravis
Clinical Predictors of Relapse in a Cohort of Steroid-Treated Patients With Well-Controlled Myasthenia Gravis Open
Objective Despite the high efficiency of glucocorticoids (GCs), ~18–34% patients with myasthenia gravis (MG) may experience relapses of the disease. Here, we aim to identify clinical factors related to relapses during steroid tapering or a…
View article: Different sensorimotor mechanism in fast and slow progression amyotrophic lateral sclerosis
Different sensorimotor mechanism in fast and slow progression amyotrophic lateral sclerosis Open
The huge heterogeneity of the disease progression rate may cause inconsistent findings between local activity and functional connectivity of the primary sensorimotor area (PSMA) in amyotrophic lateral sclerosis (ALS). For illustration of t…
View article: Delayed Respiratory Insufficiency and Extramuscular Abnormalities in Selenoprotein N-Related Myopathies
Delayed Respiratory Insufficiency and Extramuscular Abnormalities in Selenoprotein N-Related Myopathies Open
Background: Selenoprotein N-related myopathies (SEPN1-RMs) are a subset of congenital myopathies caused by mutations of Selenoprotein N gene ( SELENON or SEPN1 ). Clinical phenotype is considered as highly consistent and little attention h…
View article: Missense Mutations of Codon 116 in the SOD1 Gene Cause Rapid Progressive Familial ALS and Predict Short Viability With PMA Phenotype
Missense Mutations of Codon 116 in the SOD1 Gene Cause Rapid Progressive Familial ALS and Predict Short Viability With PMA Phenotype Open
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease, characterized by a great variety of both clinical presentations and genetic causes. Previous studies had identified two different missense mutations in SO…
View article: Characterization of Genotype–Phenotype Correlation With MORC2 Mutated Axonal Charcot–Marie–Tooth Disease in a Cohort of Chinese Patients
Characterization of Genotype–Phenotype Correlation With MORC2 Mutated Axonal Charcot–Marie–Tooth Disease in a Cohort of Chinese Patients Open
Objective Charcot –Marie–Tooth (CMT) disease is an exciting field of study, with a growing number of causal genes and an expanding phenotypic spectrum. The microrchidia family CW-type zinc finger 2 gene (MORC2) was newly identified as a ca…
View article: VNTR2/VNTR3 genotype in the <i>FCGRT</i> gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravis
VNTR2/VNTR3 genotype in the <i>FCGRT</i> gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravis Open
Background: Intravenous immunoglobulin (IVIG) has been commonly used to treat myasthenia gravis exacerbation, but is still ineffective in nearly 30% of patients. A variable number of tandem repeat (VNTR) polymorphism in the FCGRT gene has …
View article: Favorable Effects of Tacrolimus Monotherapy on Myasthenia Gravis Patients
Favorable Effects of Tacrolimus Monotherapy on Myasthenia Gravis Patients Open
Background and Purpose: Tacrolimus (TAC) has been proven to be a rapid-acting, steroid-sparing agent for myasthenia gravis (MG) therapy. However, evidence related to the effectiveness of TAC alone is rare. Therefore, this study was perform…
View article: Determinants of the repetitive-CMAP occurrence and therapy efficacy in slow-channel myasthenia
Determinants of the repetitive-CMAP occurrence and therapy efficacy in slow-channel myasthenia Open
This study provides Class IV evidence that channel blocker therapy in patients with SCCMS improves symptoms.